At a glance
ClinicalIndex Comparison RecordN/ACompleted· 338 enrolled
Drug / intervention
erlotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice
In Brief
An observational study evaluating erlotinib and gemcitabine for Pancreatic Cancer. Completed, enrolled 338 participants across 1 site.
Detailed Summary
This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedFeb 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedFeb 4, 2013
Enrollment StartMar 31, 2012
Primary CompletionFeb 28, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.4 years ago
Interventions
erlotinibdrug
Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
gemcitabinedrug
Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)